31 studies found for:
"Encephalitis, Tick-Borne"
Create an RSS feed from your search for:
Download the search results for:Display Options
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Recruiting |
A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL Baxter) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory
|
||||
| 2 | Active, not recruiting |
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
|
||||
| 3 | Completed |
TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)
|
||||
| 4 | Completed |
An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE
|
||||
| 5 | Completed |
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
|
||||
| 6 | Completed |
TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)
|
||||
| 7 | Completed |
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
|
||||
| 8 | Active, not recruiting |
Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
|
||||
| 9 | Completed |
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
|
||||
| 10 | Completed |
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
|
||||
| 11 | Completed |
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
|
||||
| 12 | Completed |
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
|
||||
| 13 | Completed |
FSME IMMUN NEW Follow-Up to Study 208 in Volunteers Aged 16 to 66 Years
|
||||
| 14 | Recruiting |
Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac
|
||||
| 15 | Completed |
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
|
||||
| 16 | Completed |
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
|
||||
| 17 | Completed |
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
|
||||
| 18 | Completed |
FSME IMMUN NEW Follow-Up to Study 199 in Children Aged 1 to 6 Years
|
||||
| 19 | Completed |
Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
|
||||
| 20 | Completed |
FSME IMMUN NEW Follow-Up to Study 205 in Children Aged 6 to 16 Years
|
† Indicates status has not been verified in more than two years